Urologic Survey (Functional Urology)

Re: Comparative Effectiveness of Combined Low- and Standart-Dose Trospium and Solifenacin for Moderate Overactive Bladder Symptoms in Elderly Men and Women


  • Ilker Sen

J Urol Surg 2015;2(1):45-45

Overactive bladder (OAB) treatment is also a problem in elderly people. Treatment alternatives are limited especially in elderly patients who were resistant to standart antimuscarinic treatments. In this study, the authors examined a group of elderly patients with OAB, who had an episode of incontinence (EI) three or less a day and unsatisfied with the treatment, and low dose (Trospium 15mg/day+Solifenacin 5 mg/day) versus standart dose (Trospium 30mg/day+Solifenacin 10 mg/day) trospium+solifenacin treatments were evaluated. The assignment of patients was random and blind in this placebo-controlled study. Urodynamic study, ICIQ-SF questionnaires and bladder diaries were used. Significant improvement in symptoms and urodynamic parameters were seen in both treatment groups. The frequency of EI in both of the main groups decreased by almost 2-fold compared to the initial data. Side effects were more in standart dose group. They concluded that, as the treatment efficacy of both groups was similiar, combination of these drugs in standart doses for such patients is excessive. Also the authors discussed that synergistic effects of combination of antimuscarinics were more effective than high doses. Search for non-invasive tretment alternatives in antimuscarinic resistant OAB is ongoing.